0001140361-14-027278.txt : 20140701
0001140361-14-027278.hdr.sgml : 20140701
20140701173944
ACCESSION NUMBER: 0001140361-14-027278
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140627
FILED AS OF DATE: 20140701
DATE AS OF CHANGE: 20140701
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9143477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanofi
CENTRAL INDEX KEY: 0001121404
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: I0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 14953680
BUSINESS ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
BUSINESS PHONE: 33153774400
MAIL ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
FORMER NAME:
FORMER CONFORMED NAME: SANOFI-AVENTIS
DATE OF NAME CHANGE: 20040826
FORMER NAME:
FORMER CONFORMED NAME: SANOFI SYNTHELABO SA
DATE OF NAME CHANGE: 20010104
4
1
doc1.xml
FORM 4
X0306
4
2014-06-27
0
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001121404
Sanofi
54, RUE LA BOETIE
PARIS
I0
75008
FRANCE
0
0
1
0
Common Stock
2014-06-27
4
P
0
10105
272.6967
A
20218946
I
See note
Common Stock
2014-06-27
4
P
0
2011
273.8054
A
20220957
I
See note
Common Stock
2014-06-27
4
P
0
4593
274.7689
A
20225550
I
See note
Common Stock
2014-06-27
4
P
0
15394
275.8115
A
20240944
I
See note
Common Stock
2014-06-27
4
P
0
16131
276.8007
A
20257075
I
See note
Common Stock
2014-06-27
4
P
0
1766
277.4302
A
20258841
I
See note
Common Stock
2014-06-30
4
P
0
524
275.6790
A
20259365
I
See note
Common Stock
2014-06-30
4
P
0
4725
276.3318
A
20264090
I
See note
Common Stock
2014-06-30
4
P
0
1600
277.2924
A
20265690
I
See note
Common Stock
2014-06-30
4
P
0
3160
278.3020
A
20268850
I
See note
Common Stock
2014-06-30
4
P
0
6844
280.0328
A
20275694
I
See note
Common Stock
2014-06-30
4
P
0
20665
280.7446
A
20296359
I
See note
Common Stock
2014-06-30
4
P
0
25643
281.8940
A
20322002
I
See note
Common Stock
2014-06-30
4
P
0
79511
282.9111
A
20401513
I
See note
Common Stock
2014-06-30
4
P
0
62704
283.8328
A
20464217
I
See note
Common Stock
2014-06-30
4
P
0
7024
284.5270
A
20471241
I
See note
The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). The shares were purchased pursuant to a plan intended to comply with Rule 10b5-1(c)(1)(i) under the Exchange Act, entered into with a broker on June 27, 2014.
Purchase prices range from $272.25 to $273.22 per share, inclusive.
Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 17,671,689 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuers Board of Directors.
Purchase prices range from $273.30 to $274.13 per share, inclusive.
Purchase prices range from $274.32 to $275.29 per share, inclusive.
Purchase prices range from $275.32 to $276.31 per share, inclusive.
Purchase prices range from $276.34 to $277.33 per share, inclusive.
Purchase prices range from $277.34 to $277.57 per share, inclusive.
Purchase prices range from $275.05 to $276.00 per share, inclusive.
Purchase prices range from $276.06 to $277.00 per share, inclusive.
Purchase prices range from $277.10 to $278.09 per share, inclusive.
Purchase prices range from $278.10 to $278.98 per share, inclusive.
Purchase prices range from $279.29 to $280.28 per share, inclusive.
Purchase prices range from $280.30 to $281.29 per share, inclusive.
Purchase prices range from $281.32 to $282.31 per share, inclusive.
Purchase prices range from $282.32 to $283.31 per share, inclusive.
Purchase prices range from $283.32 to $284.31 per share, inclusive.
Purchase prices range from $284.33 to $284.82 per share, inclusive.
/s/ John Felitti, Associate Vice President, Corporate Law, Financial & Securities Law
2014-07-01